TLR7/8 agonist induces a post-entry SAMHD1-independent block to HIV-1 infection of monocytes
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1742-4690
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
TLR7/8 agonist induces a post-entry SAMHD1-independent block to HIV-1 infection of monocytes ; volume:13 ; number:1 ; day:1 ; month:12 ; year:2016 ; pages:1-14 ; date:12.2016
Retrovirology ; 13, Heft 1 (1.12.2016), 1-14, 12.2016
- Urheber
-
Hofmann, Henning
- Beteiligte Personen und Organisationen
-
Vanwalscappel, Bénédicte
Bloch, Nicolin
Landau, Nathaniel R.
SpringerLink (Online service)
- DOI
-
10.1186/s12977-016-0316-3
- URN
-
urn:nbn:de:1111-201612205171
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:51 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Hofmann, Henning
- Vanwalscappel, Bénédicte
- Bloch, Nicolin
- Landau, Nathaniel R.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Deoxyguanosine is a TLR7 agonist
Whole blood targeting and activation of monocytes with TLR7 agonist formulated in cationic liposomes
Intratumoral immunotherapy with the TLR7/8 agonist 3M-052
The TLR7 agonist Imiquimod promote the immunogenicity of msenchymal stem cells
Migrationsverhalten von NK-Zellen nach Stimulation mit dem TLR7-Agonisten Resiquimod
R-848 triggers the expression of TLR7/8 and suppresses HIV replication in monocytes
Lignin-chitosan-based biocomposite film for the localized delivery of TLR7 agonist imiquimod
TLR7 Ligation Inhibits TLR8 Responsiveness in IL-27-Primed Human THP-1 Monocytes and Macrophages
T cell-independent eradication of experimental glioma by intravenous TLR7/8-agonist-loaded nanoparticles
Gastric cancer vaccines synthesized using a TLR7 agonist and their synergistic antitumor effects with 5-fluorouracil
Development of a TLR7/8 agonist adjuvant formulation to overcome early life hyporesponsiveness to DTaP vaccination
Non-thermal plasma treatment induces MAPK signaling in human monocytes
Deoxyguanosine is a TLR7 agonist
Whole blood targeting and activation of monocytes with TLR7 agonist formulated in cationic liposomes
Intratumoral immunotherapy with the TLR7/8 agonist 3M-052
The TLR7 agonist Imiquimod promote the immunogenicity of msenchymal stem cells
Migrationsverhalten von NK-Zellen nach Stimulation mit dem TLR7-Agonisten Resiquimod
R-848 triggers the expression of TLR7/8 and suppresses HIV replication in monocytes
Lignin-chitosan-based biocomposite film for the localized delivery of TLR7 agonist imiquimod
TLR7 Ligation Inhibits TLR8 Responsiveness in IL-27-Primed Human THP-1 Monocytes and Macrophages
T cell-independent eradication of experimental glioma by intravenous TLR7/8-agonist-loaded nanoparticles
Gastric cancer vaccines synthesized using a TLR7 agonist and their synergistic antitumor effects with 5-fluorouracil
Development of a TLR7/8 agonist adjuvant formulation to overcome early life hyporesponsiveness to DTaP vaccination
Non-thermal plasma treatment induces MAPK signaling in human monocytes
Deoxyguanosine is a TLR7 agonist
Whole blood targeting and activation of monocytes with TLR7 agonist formulated in cationic liposomes
Intratumoral immunotherapy with the TLR7/8 agonist 3M-052
The TLR7 agonist Imiquimod promote the immunogenicity of msenchymal stem cells
Migrationsverhalten von NK-Zellen nach Stimulation mit dem TLR7-Agonisten Resiquimod
R-848 triggers the expression of TLR7/8 and suppresses HIV replication in monocytes
Lignin-chitosan-based biocomposite film for the localized delivery of TLR7 agonist imiquimod
TLR7 Ligation Inhibits TLR8 Responsiveness in IL-27-Primed Human THP-1 Monocytes and Macrophages
T cell-independent eradication of experimental glioma by intravenous TLR7/8-agonist-loaded nanoparticles
Gastric cancer vaccines synthesized using a TLR7 agonist and their synergistic antitumor effects with 5-fluorouracil
Development of a TLR7/8 agonist adjuvant formulation to overcome early life hyporesponsiveness to DTaP vaccination